Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Melanocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Melanocytic Neoplasm

Cancer Family

Melanocytic Neoplasm

CI-CAN-00000026Explore in graph →

Non-malignant610 active trials13 approved drugs233 evidence items

NCIt: C7058

Overview
Statistics
Survival
Genomics26
Variants & evidence233
Drugs64
Trials3258
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (196)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 196 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Improved overall survival in melanoma with combined dabrafenib and trametinib.
· N Engl J Med · 2015 · PMID 25399551 · validated civic_curation pubmed
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
· Lancet Oncol · 2016 · PMID 27480103 · validated civic_curation pubmed
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
· Lancet Oncol · 2018 · PMID 29573941 · validated civic_curation pubmed
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet · 2020 · PMID 32534646 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697 · validated civic_curation pubmed
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
· J Clin Oncol · 2011 · PMID 21343559 · validated civic_curation pubmed
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

Showing 51–75 of 196 publications

← Previous
1
2
3
4
…
8
Next →

· J Clin Pathol · 2013 · PMID 23463675 · validated civic_curation pubmed

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.

· Clin Cancer Res · 2014 · PMID 24583796 · validated civic_curation pubmed

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

· Lancet Oncol · 2014 · PMID 24508103 · validated civic_curation pubmed

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28284557 · validated civic_curation pubmed

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

· N Engl J Med · 2017 · PMID 28891408 · validated civic_curation pubmed

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

· N Engl J Med · 2014 · PMID 25265492 · validated civic_curation pubmed

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

· J Clin Oncol · 2013 · PMID 23569304 · validated civic_curation pubmed

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

· Br J Dermatol · 2011 · PMID 21166657 · validated civic_curation pubmed

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

· PLoS One · 2015 · PMID 26086854 · validated civic_curation pubmed

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

· Lancet · 2012 · PMID 22608338 · validated civic_curation pubmed

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

· N Engl J Med · 2014 · PMID 25265494 · validated civic_curation pubmed

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

· Cell · 2015 · PMID 26359985 · validated civic_curation pubmed

Inhibition of mutated, activated BRAF in metastatic melanoma.

· N Engl J Med · 2010 · PMID 20818844 · validated civic_curation pubmed

Improved survival with MEK inhibition in BRAF-mutated melanoma.

· N Engl J Med · 2012 · PMID 22663011 · validated civic_curation pubmed

GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma.

· Eur J Med Res · 2010 · PMID 21156401 · validated civic_curation pubmed

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

· N Engl J Med · 2012 · PMID 23020132 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

· PLoS One · 2013 · PMID 23861977 · validated civic_curation pubmed

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

· J Clin Oncol · 2013 · PMID 23775962 · validated civic_curation pubmed